FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289523172> ?p ?o ?g. }

• W4289523172 endingPage "4726" @default.
• W4289523172 startingPage "4716" @default.
• W4289523172 abstract "To compare the treatment response and progression-free survival (PFS) in advanced hepatocellular carcinoma (HCC) patients who received sorafenib treatment either alone or combined with radioembolization (RE).Follow-up images of the patients treated within a multicenter phase II trial (SORAMIC) were assessed by mRECIST. A total of 177 patients (73 combination arm [RE + sorafenib] and 104 sorafenib arm) were included in this post-hoc analysis. Response and progression characteristics were compared between treatment arms. Survival analyses were done to compare PFS and post-progression survival between treatment arms. Multivariate Cox regression analysis was used to compare survival with factors known to influence PFS in patients with HCC.The combination arm had significantly higher objective response rate (61.6% vs. 29.8%, p < 0.001), complete response rate (13.7% vs. 3.8%, p = 0.022), and a trend for higher disease control rate (79.2% vs. 72.1%, p = 0.075). Progression was encountered in 116 (65.5%) patients and was more common in the sorafenib arm (75% vs. 52.0%, p = 0.001). PFS (median 8.9 vs. 5.4 months, p = 0.022) and hepatic PFS were significantly better in the combination arm (9.0 vs. 5.7 months, p = 0.014). Multivariate analysis confirmed the treatment arm as an independent predictor of PFS.In advanced HCC patients receiving sorafenib, combination with RE has an additive anticancer effect on sorafenib treatment resulting in a higher and longer tumor response. However, the enhanced response did not translate into prolonged survival. Better patient selection and superselective treatment could improve outcomes after combination therapy." @default.
• W4289523172 created "2022-08-03" @default.
• W4289523172 creator A5001010553 @default.
• W4289523172 creator A5006663456 @default.
• W4289523172 creator A5011265052 @default.
• W4289523172 creator A5012255962 @default.
• W4289523172 creator A5016425452 @default.
• W4289523172 creator A5018121001 @default.
• W4289523172 creator A5023994552 @default.
• W4289523172 creator A5027677772 @default.
• W4289523172 creator A5028863833 @default.
• W4289523172 creator A5030331048 @default.
• W4289523172 creator A5031340334 @default.
• W4289523172 creator A5037412930 @default.
• W4289523172 creator A5043342057 @default.
• W4289523172 creator A5046852939 @default.
• W4289523172 creator A5047030030 @default.
• W4289523172 creator A5048296619 @default.
• W4289523172 creator A5057457186 @default.
• W4289523172 creator A5057700552 @default.
• W4289523172 creator A5060175272 @default.
• W4289523172 creator A5082309779 @default.
• W4289523172 creator A5083262852 @default.
• W4289523172 creator A5085766415 @default.
• W4289523172 creator A5089915345 @default.
• W4289523172 date "2022-08-02" @default.
• W4289523172 modified "2023-09-30" @default.
• W4289523172 title "Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib" @default.
• W4289523172 cites W1535440056 @default.
• W4289523172 cites W1584669207 @default.
• W4289523172 cites W1859381337 @default.
• W4289523172 cites W1933451634 @default.
• W4289523172 cites W1966969960 @default.
• W4289523172 cites W1971837077 @default.
• W4289523172 cites W1981536905 @default.
• W4289523172 cites W1994193851 @default.
• W4289523172 cites W1998417832 @default.
• W4289523172 cites W2000307707 @default.
• W4289523172 cites W2037501213 @default.
• W4289523172 cites W2066593706 @default.
• W4289523172 cites W2086804632 @default.
• W4289523172 cites W2136462552 @default.
• W4289523172 cites W2142020092 @default.
• W4289523172 cites W2152033211 @default.
• W4289523172 cites W2502891277 @default.
• W4289523172 cites W2560499218 @default.
• W4289523172 cites W2746343077 @default.
• W4289523172 cites W2765356289 @default.
• W4289523172 cites W2791703762 @default.
• W4289523172 cites W2809889937 @default.
• W4289523172 cites W2908573150 @default.
• W4289523172 cites W2921294187 @default.
• W4289523172 cites W2968989098 @default.
• W4289523172 cites W2980236331 @default.
• W4289523172 cites W3000125713 @default.
• W4289523172 cites W3005975331 @default.
• W4289523172 cites W3012814711 @default.
• W4289523172 cites W3025022288 @default.
• W4289523172 cites W3040084298 @default.
• W4289523172 cites W3047612202 @default.
• W4289523172 cites W3080847075 @default.
• W4289523172 cites W3089047398 @default.
• W4289523172 cites W3089552331 @default.
• W4289523172 cites W3096906134 @default.
• W4289523172 cites W3106085383 @default.
• W4289523172 cites W3130077464 @default.
• W4289523172 cites W3137696361 @default.
• W4289523172 cites W3142573131 @default.
• W4289523172 cites W3195905256 @default.
• W4289523172 cites W3197550890 @default.
• W4289523172 cites W3208952443 @default.
• W4289523172 cites W4200388794 @default.
• W4289523172 cites W4206788213 @default.
• W4289523172 doi "https://doi.org/10.1007/s00259-022-05920-8" @default.
• W4289523172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35916920" @default.
• W4289523172 hasPublicationYear "2022" @default.
• W4289523172 type Work @default.
• W4289523172 citedByCount "1" @default.
• W4289523172 countsByYear W42895231722023 @default.
• W4289523172 crossrefType "journal-article" @default.
• W4289523172 hasAuthorship W4289523172A5001010553 @default.
• W4289523172 hasAuthorship W4289523172A5006663456 @default.
• W4289523172 hasAuthorship W4289523172A5011265052 @default.
• W4289523172 hasAuthorship W4289523172A5012255962 @default.
• W4289523172 hasAuthorship W4289523172A5016425452 @default.
• W4289523172 hasAuthorship W4289523172A5018121001 @default.
• W4289523172 hasAuthorship W4289523172A5023994552 @default.
• W4289523172 hasAuthorship W4289523172A5027677772 @default.
• W4289523172 hasAuthorship W4289523172A5028863833 @default.
• W4289523172 hasAuthorship W4289523172A5030331048 @default.
• W4289523172 hasAuthorship W4289523172A5031340334 @default.
• W4289523172 hasAuthorship W4289523172A5037412930 @default.
• W4289523172 hasAuthorship W4289523172A5043342057 @default.
• W4289523172 hasAuthorship W4289523172A5046852939 @default.
• W4289523172 hasAuthorship W4289523172A5047030030 @default.
• W4289523172 hasAuthorship W4289523172A5048296619 @default.
• W4289523172 hasAuthorship W4289523172A5057457186 @default.
• W4289523172 hasAuthorship W4289523172A5057700552 @default.

• next